Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ThromboGenics, Novartis sales and marketing update

ThromboGenics said Novartis' Alcon Inc. unit launched Jetrea ocriplasmin in Denmark and Sweden to treat vitreomacular

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE